ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19

Despite the availability of vaccinations, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause Coronavirus Disease 2019 (COVID-19) infection with a spectrum of disease in the acute setting. Transmission, infection, and severe disease remain common. There is a critical need...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Special Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643936/
https://www.ncbi.nlm.nih.gov/pubmed/38028354
http://dx.doi.org/10.1017/cts.2023.644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643936/
https://www.ncbi.nlm.nih.gov/pubmed/38028354
http://dx.doi.org/10.1017/cts.2023.644

Ejemplares similares